Presentation of Strong Preclinical Dataset: On September 25, 2024, HOOKIPA presented the preclinical proof-of-concept dataset ...

On March 27, 1827, the day after Ludwig van Beethoven's death, his associates uncovered a hidden trove of documents in his ...

Arbutus Biopharma (ABUS) has released an update. Arbutus Biopharma is set to present at the Jefferies London Healthcare Conference to discuss ...

Standard vaccinations include DTaP, which protects against diphtheria, tetanus and pertussis; polio; MMR, which protects ...

New Zealand approved Tune Therapeutics' TUNE-401, an epigenetic editing therapy for chronic hepatitis B, for human trials.

The researchers conducted a cohort study using data from more than 6 million adults from the Veterans Health Administration ...

TD Cowen analyst Tyler Van Buren maintained a Buy rating on Gilead Sciences (GILD – Research Report) today and set a price target of ...

While Medicare covers vaccines — including vaccines for the flu, pneumonia, hepatitis B and COVID-19 — under Part B (medical insurance) to treat exposure to a disease, Part D covers all vaccines to ...

Arbutus Biopharma Corporation (Nasdaq: ABUS), (“Arbutus” or the “Company”), a clinical-stage biopharmaceutical company ...

India faces a growing cancer crisis fueled by lifestyle choices and environmental factors. Preventing cancer may feel like a ...

Tune Therapeutics Moves into Clinical Spotlight with TUNE-401: A First-in-Class Epigenetic Silencer for Hepatitis B ...